Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant

• Ayalew Tefferi,
• Animesh Pardanani,
• Kebede H. Begna,
• Aref Al-Kali,
• William J. Hogan,
• Mark R. Litzow,
• Rhett P. Ketterling,
• Kaaren K. Reichard,
• Naseema Gangat

Affiliations

Ayalew Tefferi

Division of Hematology, Mayo Clinic

Animesh Pardanani

Division of Hematology, Mayo Clinic

Kebede H. Begna

Division of Hematology, Mayo Clinic

Aref Al-Kali

Division of Hematology, Mayo Clinic

William J. Hogan

Division of Hematology, Mayo Clinic

Mark R. Litzow

Division of Hematology, Mayo Clinic

Rhett P. Ketterling

Division of Hematopathology, Mayo Clinic

Kaaren K. Reichard

Division of Hematopathology, Mayo Clinic

Naseema Gangat

Division of Hematology, Mayo Clinic